All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
FDA clears investigational new drug application for ‘OncoMimic’ based immunotherapy EO2463
On March 24, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for EO2463, an ‘OncoMimic’ based immunotherapy being investigated for the treatment of indolent non-Hodgkin lymphoma.
A phase I/II clinical trial (NCT04669171), expected to be initiated in Q2 2021, will evaluate the safety, tolerability, and efficacy of EO2463 as a monotherapy and in combination with standard of care (rituximab, and rituximab plus lenalidomide) in 60 patients with follicular lymphoma and marginal zone lymphoma.
EO2463
EO2463 is a novel investigational immunotherapy that comprises four peptides, derived from bacteria present in the gut microbiome, which mimic B lymphocyte-specific lineage markers. The ‘OncoMimic’ based therapy is designed to induce full depletion of the malignant B lymphocytes that are enriched in indolent non-Hodgkin lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content